PCSK9 and cardiovascular disorder: In addition to monoclonal antibodies, a small interfering RNA drug targeting PCSK9, inclisiran, has also been approved for treating cardiovascular diseases by lowering LDL-C levels in patients.14,15 Inclisiran functions by reducing the expression of PCSK9 and is administered subcutaneously at the beginning of treatment, again after 3 months, and thereafter every 6 months.